A case study published recently in Transfusion involving an extremely rare dual diagnosis of both hemolytic disease of the fetus and newborn (HDFN) and fetal and neonatal alloimmune thrombocytopenia (FNAIT) underscored the intricate challenges faced in neonatal care.
The study authors stated that to their knowledge, this is the first reported case of co-existing HDFN and FNAIT in the current scientific literature.
In a groundbreaking case, a 35-week gestation infant was born to a mother with RhD alloimmunization and severe fetal anemia, as indicated by elevated middle cerebral artery Doppler values. While initially treated for HDFN with red blood cell transfusions, intravenous immunoglobulin, and phototherapy, the neonate also exhibited severe thrombocytopenia, with a platelet count as low as 3,000/μL.
“To our knowledge, this is the first reported case of co-existing HDFN and FNAIT in the scientific literature,” the study authors wrote. “The baby was discharged after a 19-day hospital course with a hemoglobin of 14.8 g/dL and platelet count of 149 x 103/μL.”
This severe thrombocytopenia, unexpected in the context of HDFN, led clinicians to suspect concurrent FNAIT. Maternal serum testing revealed anti-HPA-1a antibodies, confirmed through specialized antibody screening and testing via polymerase chain reaction. The neonate, heterozygous for HPA-1a and HPA-1b antigens, also expressed HLA antigens A1, A24, and B8. Concurrent maternal HLA antibodies against A1 and other specificities suggested additional immune interactions contributing to the condition.
Read more about FNAIT testing and diagnosis
Treatment for the thrombocytopenia included platelet transfusions, which successfully increased the count to 144,000/μL. This intervention stabilized the neonate’s condition, enabling discharge after a 19-day hospital stay with improved hemoglobin (14.8 g/dL) and platelet levels (149,000/μL). The coordinated management of both conditions highlighted the importance of early recognition and tailored therapies in complex neonatal cases.
This unique case is the first reported instance of coexisting HDFN and FNAIT, revealing a need for heightened clinical awareness when severe thrombocytopenia occurs in the setting of HDFN. Advanced diagnostic tools, including solid-phase antibody assays and polymerase chain reaction, played a critical role in identifying the underlying causes and guiding effective treatment plans.
Families facing similar diagnoses can take heart in the significant progress made in understanding and managing these intertwined conditions. Early intervention and precise treatments not only improve immediate neonatal outcomes but also provide a clearer roadmap for addressing potential complications in future pregnancies. As research into these overlapping immune-mediated disorders continues, further advancements may lead to even better outcomes for affected families.
